• US: +1 9176726599
  • Login

Antibody Cocktails Market Status (2016-2020) and Forecast Market Analysis, Regional Outlook, Segment Growth Potential, and Competitive Market Share Analysis, 2021-2027

Format: PDF | Pages: 333 | Report ID: MRS1130


Report Description

The global Antibody Cocktails market size is estimated at USD XX million in 2020, expanding at a CAGR of 6.8% from 2021 to 2027 to reach XX Million USD in 2027.

Market Dynamics

An antibody, also known as immunoglobulin, is a protective protein produced by the body's immune system in response to the presence of a foreign substance known as an antigen. Antigens are a diverse group of substances that include pathogenic organisms as well as toxic materials such as insect venom, bacteria, or viruses. An antibody cocktail is a mixture or cocktail of two different antibodies. The rationale for combining two antibodies in a cocktail approach is to reduce viral mutational escape.

The increasing use of inorganic strategies such as partnerships and agreements by key market players is expected to drive market growth during the forecast period. For example, in May 2021, F. Hoffmann-La Roche Ltd., a multinational healthcare company, and Cipla Inc., a multinational pharmaceutical company, formed a strategic partnership under which F. Hoffmann-La Roche Ltd. will import its antibody cocktail (Casirivimab and Imdevimab) medication into India, where it will be marketed and distributed through Cipla's distribution network.

Regional Insights

The antibody cocktails market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America held the largest share of the custom antibody market in 2020. This region's large share can be attributed to rising investments in the development of structure-based drug designs, expanding research in genomics and proteomics, rising demand for high-quality research tools for data reproducibility, and a growing emphasis on developing antibody-based therapeutics. Another important factor contributing to this market segment's large share is the presence of a large number of global players in this region.

Segment Insights

The Antibody Cocktails market is fragmented into type, indication and distribution channel segments. Based on the type, the monovalent are anticipated to dominate the market. Based on the indication, the COVID-19 indication showcased the highest CAGR in the forecast period.  By distribution channel, online pharmacies showcased highest CAGR.

Competitive Insights

Key companies in the Antibody Cocktails Market include Cipla Inc., Hoffmann, La Roche Ltd, Regeneron Pharmaceuticals Inc., Zydus Cadila, AstraZeneca, Aridis Pharmaceuticals Inc., Immunome Inc. and Eli Lilly and Company. For example, in May 2021, F. Hoffmann-La Roche Ltd., a multinational healthcare company, and Cipla Inc., a multinational pharmaceutical company, formed a strategic partnership under which F. Hoffmann-La Roche Ltd. will import its antibody cocktail (Casirivimab and Imdevimab) medication into India, where it will be marketed and distributed through Cipla's distribution network.

The report begins with an overview of the Industry Chain structure, and describes the industry environment, then analyses market size and forecast of Antibody Cocktails by type, indication, distribution and region. In addition, this report introduces the market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.

Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products etc.):

  • Cipla
  • Hoffmann-La Roche Ltd
  • Regeneron Pharmaceuticals Inc.
  • Zydus Cadila
  • AstraZeneca
  • Aridis Pharmaceuticals Inc.
  • AstraZene Immunome Inc.
  • Celltrion Healthcare Co., Ltd.
  • Eli Lilly and Company

Type Coverage (Market Size & Forecast, Main Consumer Analysis etc.):

  • Monovalent antibody
  • Polyvalent antibody

Indication Coverage (Market Size & Forecast, Main Consumer Analysis etc.):

  • COVID-19
  • Cancer
  • HIV
  • Others

Distribution Channel Coverage (Market Size & Forecast, Main Consumer Analysis etc.):

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region Coverage (Regional Consumption, Demand & Forecast by Countries etc.):

  • North America (U.S., and Canada)
  • Europe (Germany, U.K., France, Italy, Spain etc.)
  • Asia-Pacific (China, India, Japan, Indonesia, Malaysia, Australia, South Korea, etc.)
  • South America (Brazil, Mexico, Argentina etc.)
  • Middle East & Africa (Saudi Arabia, Kuwait, UAE, South Africa etc.)

Frequently Asked Questions

The global Antibody Cocktails market size is estimated at USD XX million in 2020, expanding at a CAGR of 6.8% from 2021 to 2027 to reach XX Million USD in 2027.
North America captured the highest revenue in 2021 and is projected to continue its dominance during the study period.
The global Antibody Cocktails market size is expanding at a CAGR of 6.8% from 2021 to 2027 to reach XX Million USD in 2027.
Asia Pacific (especially China, and India) region is projected to grow at the fastest growth rate during the study period.
Key companies in the Antibody Cocktails Market include Cipla Inc., Hoffmann, La Roche Ltd, Regeneron Pharmaceuticals Inc., Zydus Cadila, AstraZeneca, Aridis Pharmaceuticals Inc., Immunome Inc. and Eli Lilly and Company. For example, in May 2021, F. Hoffmann-La Roche Ltd., a multinational healthcare company, and Cipla Inc., a multinational pharmaceutical company, formed a strategic partnership under which F. Hoffmann-La Roche Ltd. will import its antibody cocktail (Casirivimab and Imdevimab) medication into India, where it will be marketed and distributed through Cipla's distribution network.

Why Choose Market Research Strategy?

  Authenticated Data Sources

We utilize market analysis/information from verified authenticated data sources to scoop accurate research reports

  Express Delivery

We understand the urgency of our clients and their clients' in the competitive space thus, deliver the report in minimum turnaround

  Gain Instant Access

Without further ado, choose us and get instant access to reliable analysis to help you make the right business decisions.

  Our Pledge to You

We abide by the information security policy and adheres to keep your private and business information confidential and secure.

Copyright © 2022 Market Research Strategy, All rights reserved.